1	Title page
2	Title: The time is ripe to harmonize global acute febrile illness etiologic investigations
3	Running title: Harmonization of acute febrile illness investigations methods
4	Article category: Brief Report
5	Author names & institutional affiliations: José Moreira <sup>1,2</sup> , B. Leticia Fernando-Carballo <sup>3</sup> ,
6	Camille Escadafal <sup>3</sup> , Sabine Dittrich <sup>3,4</sup> , Patrícia Brasil <sup>1</sup> , André M Siqueira <sup>1</sup>
7	Affiliations:
8	1.Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de
9	Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
10	2. Instituto Nacional de Cardiologia, Departamento de Ensino e Pesquisa, Rio de Janeiro,
11	Brazil
12	3. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
13	4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
14	Corresponding author: José Moreira MD Ph.D; e-mail: jose.moreira@ini.fiocruz.br;
15	telephone number: +55 (21) 97035-8843; Laboratório de Pesquisa Clínica em Doenças Febris
16	Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av.
17	Brasil, 4365 – Manguinhos, Rio de Janeiro, Brazil, CEP: 21040-360; Twitter: @j_moreira_
18	
19	
20	
21	
22	
23	
24	
25	

26	Abstract
27	We investigated the impact of considering different case definitions of fever as inclusion criteria
28	among participants enrolling in an acute febrile illness investigation and observed that adopting a
29	subjective assessment of fever regardless of specific fever cut-off value accounted for the
30	diversity of clinical fever phenotypes and did not mischaracterize the febrile population.
31	Keywords: Antipyretic therapy; Fever; Acute febrile illness; Dipyrone; Methodology
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	

50 **Text** 

#### 51 Introduction

52 Acute febrile illness (AFI) is a common reason for people seeking care and represents a range 53 of infectious and non-infectious diseases, with wide variation by region of the globe [1]. AFI 54 investigations aim to provide national and subregional epidemiology and infectious diseases 55 surveillance and to inform treatment guidelines about empirical and pathogen-specific 56 management algorithms to prioritize interventions and funding. Several AFI investigations 57 have been conducted primarily in Southeast Asia, with few global initiatives in resource-58 constrained countries [2]. However, there is no standardized approach to conducting such 59 studies, limiting the interpretation and comparability of study findings.

We were involved in a multinational project around fever host-biomarkers [3] and aimed to conduct a pilot study to inform the best criteria for our study site selection. We hypothesized that adopting a subjective or self-reported fever assessment as part of our inclusion criteria would increase the sensitivity threshold for a broad array of febrile clinical phenotypes rather than specifying a cut-off value for fever at presentation. Another hypothesis was that the recent antipyretic intake – largely available over-the-counter- would lower body temperature at arrival at the Emergency Departments (EDs).

## 67 Methods

We did a cross-sectional, study of patients presenting to two urban EDs (Unidade de Pronto Atendimento Manguinhos & Unidade de Pronto Atendimento Rocha Miranda) in Rio de Janeiro, Brazil, between October 28, 2018, and March 29, 2019. The study was conducted following the Declaration of Helsinki and the Brazilian National Ethics Research Committee and was approved in August 2018 (IRB approval no:70984617.9.0000.5262). We screened all consecutive non-severe patients who presented to the EDs over the study period and included those who reported fever  $\leq$  7 days regardless of temperature measured at the EDs. 75 Research assistants prospectively collected detailed information and interviewed participants 76 or the primary caregivers to obtain data about the demographics, main chief complaint, vital 77 signs, history of fever, peak measured temperature before arrival at the EDs (temperature 78 maximum), the measured axillary temperature at the EDs, home administration of 79 antipyretics, type/dose/timing of last administration, and tests performed at the EDs. 80 Discharge diagnosis and treatment received after discharge was retrospectively collected by 81 reviewing electronic medical records. The attending physician proposed the discharge 82 diagnosis (not involved in the study), and its appropriateness was not re-evaluated. We used 83 the following definitions: fever was subjectively identified by the participant at arrival at the 84 EDs; antipyretics are mostly over-the-counter drugs that act on reducing body temperature 85 usually with added analgesic effect, and were self-administered by the participants before 86 seeking emergency care; adults those aged  $\geq 18$  years at recruitment, and non-severe AFI was 87 an illness that was codified as blue or green according to the Manchester Triage System at 88 EDs, which does not require hospital admission. We measured the axillary temperature at 89 triage and estimated the magnitude of defervescence, considering the highest measured self-90 reported temperature before EDs arrival (Tmax). Suspected infection was defined as the 91 initiation of any antimicrobial after an EDs visit.

### 92 Statistical analysis

93 Descriptive analysis was performed to characterize the distributions of several variables. A
94 Chi-square test was used to compare categorical variables between study groups. Continuous
95 variables were compared between the study groups using analysis of variance or the Kruskal96 Wallis test if those were found to be normally or non-normally distributed, respectively. We
97 dealt with missing data using the listwise deletion method (or complete case analysis).

98 A logistic regression model was performed to ascertain the effects of recent antipyretic 99 uptake on the likelihood that participants have an overt fever at EDs admission (i.e.,  $\geq$  37.5 °C). A 2-sided *p-value* less than 0.05 was considered statistically significant. All statistical
analyses were performed using SPSS software (version 26, IBM, Chicago, Illinois, USA) and
Tableau Desktop (version 2020.4.2, Tableau, Seattle, Washington, USA). The primary
outcome was to investigate the impact of considering different case definitions of fever as
inclusion criteria among febrile patients attending EDs.

105 **Results** 

106 During the study period, we triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a 107 history of fever at arrival at the ED, corresponding to a cumulative incidence of fever at EDs 108 of 24 per 100 triaged patients over the five months. These 374 febrile patients constitute our 109 study population, of whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature <110 37.5 °C,  $\geq$  37.5 °C, and no temperature measurement registered at arrival, respectively. The 111 mean age was 30.6 [range: 0-84] years, adults (82.5%) and females (54.8%) predominated 112 (Table). The median peak measured temperature before arrival at the ED was 38.8°C (38.0-113 39.0), and the median duration of fever was 1 [1-3] days.

114 Hundred ninety-eight febrile patients had a diagnosis of infection, with upper respiratory tract 115 infection (42.4%) followed by undifferentiated febrile illness (15.7%) and urinary tract 116 infection (14.6%) were the primary febrile syndromes (Supplementary Figure 1). Hundred 117 thirty-one patients were prescribed any antibiotic after EDs visit, which beta-lactams (73/131, 118 55.7%), quinolones (23/131, 17.5%) and macrolides (16/131,12.2%) were the classes most 119 commonly prescribed. Patients who had temperature  $\geq 37.5$  °C at presentation were more 120 likely to be diagnosed with an infection [76 (66%) vs. 116 (47%), crude OR: 2.2 (95% 1.4-121 (3.5) and were prescribed antibiotic most frequently compared to those with temperature <122 37.5 °C [54 (65%) vs. 75 (48%), crude OR: 2 (95% 1.1-3.5)].

123 The site of infection varied by the height of temperature mensurated at arrival at EDs 124 (p<0.001). Patients who had a temperature < 37.5 °C at presentation were more likely to be diagnosed with upper respiratory (31.6%) and urinary infections (15.4%) (Supplementary Figure 3). The most frequently etiology diagnostics recorded in those with temperature < 37.5 °C at presentation were acute pharyngitis (20/248, 8%), followed by communityacquired gastroenteritis (19/248, 7.6%), uncomplicated urinary tract infection (16/248, 6.4%), cutaneous abscess (14/248, 5.6%), and community-acquired pneumonia (9/248, 3.6%).

131 In total, 249/374 (66.6% (95% 61.5-71.3)]) subjects reported self-administering an 132 antipyretic at home within a median of 2h [IQR 2-6] before EDs admission (24.1% of the 133 febrile subjects did not recall prior antipyretics intake). Dipyrone (72.2%) was the antipyretic 134 drug most frequently administered, followed by acetaminophen (14.3%) and ibuprofen 135 (6.3%). Most antipyretic takers consumed one class (85.9%), and the median number of 136 doses taken was 2 [IQR 1-3]. Of these 249 subjects, 167/249 (67%) reported the last dose 137 administered at a mean of 2 [2-5] hours before hospital presentation. Subjects who were 138 treated with an antipyretic drug before arrival did not differ from untreated ones regarding the 139 temperature at arrival at the ED visit ( $37 \pm 0.99 \text{ vs.} 36.8 \pm 0.86, p = 0.20$ ) or the documented 140 Tmax before the ED arrival ( $38.8 \pm 0.79 \text{ vs.} 38.4 \pm 0.60, p = 0.29$ ).

The logistic regression model correctly classified 69.1% of the cases (Supplementary Table
1). Males were 2.2 times more likely to exhibit overt fever at presentation than females [aOR:
2.25, 95% CI: 1.19-4.25]. Recent antipyretic intake did not influence the pattern of fever at
presentation [aOR:0.81, 95% CI:0.34-1.97].

145 Discussion

Our study suggests that considering a subjective/self-reported fever as an inclusion criterion rather than a specific fever cut-off value (i.e.,  $\geq$  37.5 °C) at presentation for AFI etiologic investigation results in a more inclusive study population and account for the diversity of clinical fever phenotypes that are usually seen in clinical practice. Specifically, sixty-six percent of our cohort would not have been included if we restricted our inclusion criteria to a specific febrile cut-off, potentially impacting study recruitment and patient characterization. Almost half (47.8%) of febrile participants with temperature < 37.5 °C at presentation were prescribed at least one antibiotic, and their infections were mainly upper respiratory, justifying their inclusion in AFI studies. Next, our findings suggest that the ubiquitous administration of antipyretics (66.6%) observed in our setting did not influence the febrile presentation of patients attending the EDs evaluated.

157 We concur with others [2, 4] and argue that there is an urgent need to standardize AFI study 158 protocols to make sure that we can compare results from different studies and pool their 159 results to develop national, regional, or global burden of fever estimates. Such consensus in 160 AFI research would allow better comparisons, translate evidence to practice, and inform 161 treatment policy. A harmonized definition of fever would enable a more robust and consistent 162 capture of different clinical phenotypes, including those conditions where overt fever occurs 163 inconsistently, such as upper respiratory infections and uncomplicated urinary infections. 164 Others [2] have suggested an adapted STRengthening the reporting of OBservational studies 165 in Epidemiology (STROBE) checklist for conducting and reporting AFI research.

166 In conclusion, we suggest harmonizing the case definition of fever in AFI research for a 167 history of fever regardless of temperature cut-off would enable a complete picture of the 168 different clinical fever phenotypes, thus improving our understanding of the global burden of 169 febrile illness.

## 170 Author contributions

171 JM: writing original draft, visualization, conceptualization. BC: Review and editing. CE:

- 172 Review and editing. SD: review, editing. PB: conceptualization, writing, editing, supervision.
- 173 AS: conceptualization, writing, editing, supervision
- 174 Funding

- 175 The Biomarker for Fever-Diagnostic (BFF-Dx) study was funded by the Dutch, Australian,
- and UK governments.

### 177 Transparency declaration

- 178 The authors have no conflict of interest to declare.
- 179

#### 180 **References**

- Moreira J, Bressan CS, Brasil P, Siqueira AM. Epidemiology of acute febrile illness
   in Latin America. Clin Microbiol Infect. 2018; 24(8):827-835.
- 2. Rhee C, Kharod GA, Schaad N et al. Global knowledge gaps in acute febrile illness
   etiologic investigations: a scoping review. PLoS Negl Trop Dis. 2019; 13(11):
   e0007792.
- Escadafal C, Geis S, Siqueira AM, et al. Bacterial versus non-bacterial infections: a
   methodology to support use-case-driven product development of diagnostics. *BMJ Glob Health*. 2020; 5(10)e:003141.2.
- 189 4. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and
  190 without evidence-based treatments. BMC Med. 2010; 18(1):287.

191

### 192 Supplementary Tables

Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in
374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October
2018 – March 2019.

196 Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile

- 197 patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March
- 198 2019

199	Suppl	ementary	Figures
-----	-------	----------	---------

200		E. 4	A 111 1 11 1	12 1 1	c · c		C I II II II I
700	Sunnlementary	FIGHTA 1	Antihintic class	according to th	e toci ot	intection in 1	tehrile natiento
200	Supplementary	I BUIC I		accoraing to th			reprine putients

- 201 attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
- 202 Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of
- 203 infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,
- 204 October 2018-March 2019
- 205 Supplementary Figure 3. Foci of infection according to the height of temperature 206 mensurated at arrival in febrile patients attending Emergency departments in Rio de 207 Janeiro, Brazil, October 2018-March 2019
- 208 Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated
- 209 at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,

210 October 2018-March 2019

- 211
- 212
- 213
- 214

215

- 216
- 217
- 218
- 219
- 220
- 221

Table. Baseline characteristics according to the height of temperature mensurated at arrival

in febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018-

224 March 2019

225

	Total febrile population	History of fever but temperature < 37.5 °C	History of fever and temperature ≥ 37.5 °C	<i>p</i> -value
	N= 374	N= 248	N= 115	
Characteristics				
Demographics				
Age (years), mean (±SD)	31 (16)	32 (15)	28 (16)	0.02
Mala p (%)	3 (0.8)	102 ( <i>1</i> 1 E)	62 (52.0)	0.02
Tomp at arrival	109 (45.2)	103(41.5)	02(55.9)	0.0Z
(°C), mean (±SD) Missing	12 (3.2)	30.33 (0.3)	58.24 (0.0)	<b>NO.01</b>
Tmax (°C), mean (±SD)	38.7 (0.7)	38.7 (0.69)	38.95(0.9)	0.12
Missing	268 (71.7)			
Days of fever, mean (±SD) Missing	1.58 (17.4)	1.45 (21.2)	1.80 (3.2)	0.86
Degree of defervescence from Tmax, mean (±SD)	1.70 (1.13)	2.16 (0.86)	0.78 (1.04)	<0.01
Diagnosis and management				
Diagnostic testing – n (%)	76 (30.2)	42 (26.1)	32 (38.1)	0.05
Recent antibiotic use – n (%)	21 (12.2)	11 (9.6)	10 (18.9)	0.09
Missing	202 (54)			
Recent antipyretic use – n (%) Missing	249 (66.6)	169 (87.1)	76 (90.5)	0.42
IVIISSIIIg Antibiotic	50(24.1)			0.01
Antibiotic prescription – n (%)	131 (53.0)	/5 (47.8)	54 (65.1)	0.01

SD means standard deviation; Tmax higher temperature self-recorded at home before emergency department visit; Recent antibiotic use was defined as any antibiotic for systemic use started prior to emergency department visit. We excluded antibiotics for systemic use that could also be used for the treatment of tuberculosis in patients with active disease; Recent antipyretic was the use of any over-the counter antipyretic prior to emergency department visit.

### 232 Key messages

- Fever is a common reason to seek care in patients attending urban Emergency
  Departments in Rio de Janeiro, Brazil
- Suspicion of infection is the underlying cause of fever in 53% of the febrile subjects,
  and the respiratory source is the main focus of infection
- The use of antipyretics among febrile patients attending urban Emergency
   Departments in Rio de Janeiro is ubiquitous, and dipyrone is the antipyretic of choice
   in our population. However, such use did not influence overt fever presentation in
   Emergency Departments
- Our findings are essential for designing fever etiology and question the value of adopting a specific temperature cut-off for fever at enrollment, as in many fever studies. We believe that a history of fever as part of the inclusion criteria is a good surrogate of unwellness and might be incorporated systematically in future fever studies.
- 246

247

248

# Appendix Table of Contents

This supplementary material has been provided by the authors to give readers additional information about their work.

## Supplementary Tables

- Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018 March 2019.
- Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
- •

# Supplementary Figures

• Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-

March 2019

• Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending Emergency Departments in Rio de Janeiro,

Brazil, October 2018-March 2019

- Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients

attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Atb Drug Class Beta-lactam 55 Cephalosporin Macrolide 50 Penicillin Quinolone Sulfonamide 45 40 of Records 35 30 Vumber 25 20 15 10 5 0 Enteric URTI LRTI SSTI UTI AUFI

AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Antibiotic class accordingly to the foci of infection in febrile patients attending ED in Rio de Janeiro, Brazil, October 2018 - March 2019

Supplementary Figure 2. Variability in antibiotic prescription according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending ED in Rio de Janeiro, Brazil, October 2018 - March 2019



AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



- Macrolide
- Penicillin
- Quinolone
- E Sulfonamide

Supplementary Table 1. Prediction model for the likelihood of overt fever at presentation in 374 febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018 – March 2019.

Variable		Adjusted Odds Ratio (95% Cl)	<i>p</i> -value
Sex	Female	-	
	Male	2.25 (1.19-4.25)	0.01
Recent antipyretic use <sup>§</sup>	No	-	
	Yes	0.81 (0.34-1.97)	0.65
Age (years)		0.98 (0.95-1.00)	0.10
Time from fever onset (days)		1.00 (0.98-1.01)	0.97
Baseline Heart rate (beats/min)		1.050 (1.03-1.07)	< 0.05
8Non-prescription antipyre	stic untake reported by	the participant before em	argancy danartment

§Non-prescription antipyretic uptake reported by the participant before emergency department care

Dependent variable: proportion of febrile subjects with measured axillary temperature  $\ge$  37.5 °C at presentation

Supplementary Table 2. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Presumed diagnosis by febrile syndrome	Number of presentations n/N (%)	Number of patients receiving an antibiotic prescription n/N (%)		
Gastrointestinal				
Gastroenteritis	16/17 (94.11)	7/16 (43.75)		
Gastritis	1/17 (5.88)	1/1 (100)		
Upper respiratory tract infection				
Acute tonsillitis	34/84 (40.47)	34/34 (100)		
Acute pharyngitis	22/84 (26.19)	5/22 (22.72)		
Acute sinusitis	8/84 (9.52)	6/8 (75)		
Common cold	5/84 (5.95)	0/5 ( 0)		
Other upper respiratory tract infections	15/84 (17.85)	9/15 (60)		
Lower respiratory tract infection				
Acute bronchitis and COPD exacerbations	3/17 (17.64)	2/3 (66.66)		
Community-acquired pneumonia	9/17 (52.94)	8/9 (88.88)		
Influenza	2/17 (11.76)	0/2(0)		
Other lower respiratory tract infections	3/17 (17.64)	3/3 (100)		
Skin and soft tissue infection				
Cellulitis and abscesses	14/19 (73.68)	14/14 (100)		
Other infection of the skin and soft tissue	4/19 (21.05)	4/4 (100)		
Bacterial skin infection	1/19 (5.26)	1/1 (100)		
Urinary tract infection				
Uncomplicated cystitis & pyelonephritis	28/29 (96.55)	25/28 (89.28)		
Other urinary infection	1/29 (3.44)	1/1 (100)		
Acute undifferentiated febrile illness				
Arboviruses	5/30 (16.66)	0/5 (0)		
Unspecified febrile illness	6/30 (20)	4/6 (66.66)		
Leptospirosis	2/30 (6.66)	2/2 (100)		
Unspecified viral infection	15/30 (50)	1/15 (6.66)		
Other	1/30 (3.33)	1/1 (100)		
COPD stands for chronic obstructive nulmonary disease				

COPD stands for chronic obstructive pulmonary disease